GoalCode,GoalDesc,TargetCode,TargetDesc,IndicatorCode,IndicatorDesc,IndicatorTier,SeriesCode,SeriesDesc,SeriesRelease,ReportingType_Code,ReportingType_Desc,Nature_Code,Nature_Desc,Units_Code,Units_Desc,GeoArea_Code,GeoArea_Desc,Year,TimeDetail,Value,ValueType,Source,Footnotes,ISO3CD,X,Y
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,4,Afghanistan,2014.0,,40,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AFG,66.02688198,33.83160199
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,4,Afghanistan,2015.0,,65,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AFG,66.02688198,33.83160199
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,4,Afghanistan,2016.0,,65,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AFG,66.02688198,33.83160199
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2010.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2011.0,,11,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2012.0,,20,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2013.0,,33,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2014.0,,48,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2015.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,2,Africa,2016.0,,62,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,8,Albania,2011.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ALB,20.06660928,41.13897007
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,8,Albania,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ALB,20.06660928,41.13897007
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,8,Albania,2013.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ALB,20.06660928,41.13897007
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,8,Albania,2014.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ALB,20.06660928,41.13897007
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,8,Albania,2015.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ALB,20.06660928,41.13897007
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,8,Albania,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ALB,20.06660928,41.13897007
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,12,Algeria,2016.0,,61,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DZA,2.678164227,28.15940032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2008.0,,28,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2009.0,,34,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2010.0,,51,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2011.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2012.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2013.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2014.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2015.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,19,Americas,2016.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,20,Andorra,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AND,1.576257417,42.54548611
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,20,Andorra,2015.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AND,1.576257417,42.54548611
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,20,Andorra,2016.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AND,1.576257417,42.54548611
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,24,Angola,2013.0,,9,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AGO,17.57817062,-12.33724746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,24,Angola,2014.0,,45,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AGO,17.57817062,-12.33724746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,24,Angola,2015.0,,58,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AGO,17.57817062,-12.33724746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,24,Angola,2016.0,,58,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AGO,17.57817062,-12.33724746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,32,Argentina,2012.0,,41,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARG,-65.14563274,-35.19446255
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,32,Argentina,2013.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARG,-65.14563274,-35.19446255
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,32,Argentina,2014.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARG,-65.14563274,-35.19446255
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,32,Argentina,2015.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARG,-65.14563274,-35.19446255
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,32,Argentina,2016.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARG,-65.14563274,-35.19446255
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,51,Armenia,2015.0,,44,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARM,44.93839317,40.29499741
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,51,Armenia,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARM,44.93839317,40.29499741
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2009.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2010.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2011.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2012.0,,4,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2013.0,,9,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2014.0,,11,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2015.0,,16,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,142,Asia,2016.0,,20,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2008.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2009.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2010.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2011.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2012.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2013.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2014.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,36,Australia,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AUS,134.3499412,-25.57717202
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2008.0,,74.84975,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2009.0,,90.29824,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2010.0,,90.65351,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2011.0,,91.17102,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2012.0,,91.16912,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2013.0,,91.33507,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2014.0,,91.33242,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2015.0,,93.00013,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,53,Australia and New Zealand,2016.0,,93.83517,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,31,Azerbaijan,2014.0,,64,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AZE,50.01064725,40.39229544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,31,Azerbaijan,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AZE,50.01064725,40.39229544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,31,Azerbaijan,2016.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,AZE,50.01064725,40.39229544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2009.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2010.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2011.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2012.0,,37,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2013.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2014.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,44,Bahamas,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHS,-78.05111663,24.69546597
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2008.0,,14,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2009.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2010.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2011.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2013.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2014.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2015.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,48,Bahrain,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BHR,50.5490754,26.04407747
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,50,Bangladesh,2015.0,,48,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGD,89.17660788,22.86961622
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,50,Bangladesh,2016.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGD,89.17660788,22.86961622
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2009.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2010.0,,78,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2011.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2012.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2013.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2014.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2015.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,52,Barbados,2016.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRB,-59.5346489,13.13648273
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,56,Belgium,2012.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEL,4.660976456,50.64104975
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,56,Belgium,2013.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEL,4.660976456,50.64104975
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,56,Belgium,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEL,4.660976456,50.64104975
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,56,Belgium,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEL,4.660976456,50.64104975
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,56,Belgium,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEL,4.660976456,50.64104975
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,204,Benin,2011.0,,36,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEN,2.339933594,9.65401646
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,204,Benin,2012.0,,67,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEN,2.339933594,9.65401646
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,204,Benin,2013.0,,70,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEN,2.339933594,9.65401646
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,204,Benin,2014.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEN,2.339933594,9.65401646
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,204,Benin,2015.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEN,2.339933594,9.65401646
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,204,Benin,2016.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BEN,2.339933594,9.65401646
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,68,Bolivia (Plurinational State of),2014.0,,56,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BOL,-64.66224284,-16.71273412
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,68,Bolivia (Plurinational State of),2015.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BOL,-64.66224284,-16.71273412
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,68,Bolivia (Plurinational State of),2016.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BOL,-64.66224284,-16.71273412
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,72,Botswana,2012.0,,52,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BWA,23.81380223,-22.18810073
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,72,Botswana,2013.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BWA,23.81380223,-22.18810073
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,72,Botswana,2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BWA,23.81380223,-22.18810073
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,72,Botswana,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BWA,23.81380223,-22.18810073
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,72,Botswana,2016.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BWA,23.81380223,-22.18810073
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,76,Brazil,2010.0,,24,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRA,-53.08432878,-10.77668561
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,76,Brazil,2011.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRA,-53.08432878,-10.77668561
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,76,Brazil,2012.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRA,-53.08432878,-10.77668561
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,76,Brazil,2013.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRA,-53.08432878,-10.77668561
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,76,Brazil,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRA,-53.08432878,-10.77668561
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,76,Brazil,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRA,-53.08432878,-10.77668561
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,76,Brazil,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BRA,-53.08432878,-10.77668561
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,100,Bulgaria,2010.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGR,25.23763153,42.75731323
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,100,Bulgaria,2011.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGR,25.23763153,42.75731323
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,100,Bulgaria,2012.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGR,25.23763153,42.75731323
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,100,Bulgaria,2013.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGR,25.23763153,42.75731323
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,100,Bulgaria,2014.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGR,25.23763153,42.75731323
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,100,Bulgaria,2015.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGR,25.23763153,42.75731323
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,100,Bulgaria,2016.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BGR,25.23763153,42.75731323
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,854,Burkina Faso,2014.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BFA,-1.742843829,12.27491081
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,854,Burkina Faso,2015.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BFA,-1.742843829,12.27491081
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,854,Burkina Faso,2016.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BFA,-1.742843829,12.27491081
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,108,Burundi,2011.0,,14,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BDI,29.89080992,-3.366387428
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,108,Burundi,2012.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BDI,29.89080992,-3.366387428
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,108,Burundi,2013.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BDI,29.89080992,-3.366387428
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,108,Burundi,2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BDI,29.89080992,-3.366387428
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,108,Burundi,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BDI,29.89080992,-3.366387428
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,108,Burundi,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,BDI,29.89080992,-3.366387428
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,116,Cambodia,2015.0,,68,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KHM,104.922836,12.71163737
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,116,Cambodia,2016.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KHM,104.922836,12.71163737
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,120,Cameroon,2011.0,,23,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CMR,12.7419827,5.692387031
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,120,Cameroon,2012.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CMR,12.7419827,5.692387031
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,120,Cameroon,2013.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CMR,12.7419827,5.692387031
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,120,Cameroon,2014.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CMR,12.7419827,5.692387031
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,120,Cameroon,2015.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CMR,12.7419827,5.692387031
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,120,Cameroon,2016.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CMR,12.7419827,5.692387031
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2008.0,,42,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2009.0,,50,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2010.0,,58,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2011.0,,66,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2012.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2013.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2014.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2015.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,124,Canada,2016.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAN,-101.6575058,57.72360191
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2012.0,,2,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2013.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2014.0,,12,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2015.0,,11,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,29,Caribbean,2016.0,,13,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2012.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2013.0,,11,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2014.0,,18,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2015.0,,26,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,135,Caucasus and Central Asia,2016.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,140,Central African Republic,2011.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAF,20.93559492,7.003720791
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,140,Central African Republic,2012.0,,47,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAF,20.93559492,7.003720791
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,140,Central African Republic,2013.0,,23,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAF,20.93559492,7.003720791
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,140,Central African Republic,2014.0,,47,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAF,20.93559492,7.003720791
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,140,Central African Republic,2015.0,,47,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAF,20.93559492,7.003720791
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,140,Central African Republic,2016.0,,47,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CAF,20.93559492,7.003720791
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2008.0,,10,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2009.0,,33,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2010.0,,70,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2011.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2012.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2013.0,,78,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2014.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2015.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,13,Central America,2016.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2012.0,,9.22623,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2013.0,,12.90227,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2014.0,,14.30096,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2015.0,,18.11746,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,143,Central Asia,2016.0,,64.66682,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,152,Chile,2011.0,,54,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHL,-71.23029019,-35.2652885
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,152,Chile,2012.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHL,-71.23029019,-35.2652885
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,152,Chile,2013.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHL,-71.23029019,-35.2652885
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,152,Chile,2014.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHL,-71.23029019,-35.2652885
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,152,Chile,2015.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHL,-71.23029019,-35.2652885
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,152,Chile,2016.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHL,-71.23029019,-35.2652885
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,170,Colombia,2010.0,,22,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COL,-73.07446751,3.888209046
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,170,Colombia,2011.0,,46,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COL,-73.07446751,3.888209046
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,170,Colombia,2012.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COL,-73.07446751,3.888209046
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,170,Colombia,2013.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COL,-73.07446751,3.888209046
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,170,Colombia,2014.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COL,-73.07446751,3.888209046
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,170,Colombia,2015.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COL,-73.07446751,3.888209046
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,170,Colombia,2016.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COL,-73.07446751,3.888209046
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,178,Congo,2012.0,,10,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COG,15.22052612,-0.840544119
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,178,Congo,2013.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COG,15.22052612,-0.840544119
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,178,Congo,2014.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COG,15.22052612,-0.840544119
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,178,Congo,2015.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COG,15.22052612,-0.840544119
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,178,Congo,2016.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COG,15.22052612,-0.840544119
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2009.0,,48,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2010.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2011.0,,68,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2012.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2013.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2014.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,188,Costa Rica,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CRI,-84.19712782,9.970998683
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,384,Cte d'Ivoire,2014.0,,2,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CIV,-5.552690016,7.62211586
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,384,Cte d'Ivoire,2015.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CIV,-5.552690016,7.62211586
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,384,Cte d'Ivoire,2016.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CIV,-5.552690016,7.62211586
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,196,Cyprus,2015.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CYP,33.22285964,35.05659437
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,196,Cyprus,2016.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CYP,33.22285964,35.05659437
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,180,Democratic Republic of the Congo,2011.0,,9,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COD,23.65496507,-2.877154732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,180,Democratic Republic of the Congo,2012.0,,13,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COD,23.65496507,-2.877154732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,180,Democratic Republic of the Congo,2013.0,,31,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COD,23.65496507,-2.877154732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,180,Democratic Republic of the Congo,2014.0,,61,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COD,23.65496507,-2.877154732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,180,Democratic Republic of the Congo,2015.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COD,23.65496507,-2.877154732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,180,Democratic Republic of the Congo,2016.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,COD,23.65496507,-2.877154732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2009.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2010.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2011.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2012.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2013.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2015.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,208,Denmark,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DNK,9.326571283,56.03829721
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2008.0,,37,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2009.0,,41,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2010.0,,52,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2011.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2012.0,,56,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2013.0,,57,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2014.0,,58,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2015.0,,66,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,514,"Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2016.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2008.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2009.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2010.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2011.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2012.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2013.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2014.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2015.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,515,Developing regions,2016.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,262,Djibouti,2013.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DJI,42.18274707,11.56004161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,262,Djibouti,2014.0,,78,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DJI,42.18274707,11.56004161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,262,Djibouti,2015.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DJI,42.18274707,11.56004161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,262,Djibouti,2016.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DJI,42.18274707,11.56004161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,214,Dominican Republic,2014.0,,27,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DOM,-70.49847576,18.89832088
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,214,Dominican Republic,2015.0,,22,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DOM,-70.49847576,18.89832088
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,214,Dominican Republic,2016.0,,30,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DOM,-70.49847576,18.89832088
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2010.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2011.0,,15,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2012.0,,28,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2013.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2014.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2015.0,,74,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,14,Eastern Africa,2016.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2012.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2013.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2014.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2015.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,30,Eastern Asia,2016.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2008.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2009.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2010.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2011.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2013.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2014.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2015.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,518,Eastern Asia (excluding Japan),2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2009.0,,2,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2010.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2011.0,,6,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2012.0,,6,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2013.0,,6,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2014.0,,6,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2015.0,,7,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,151,Eastern Europe,2016.0,,26,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,218,Ecuador,2010.0,,17,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ECU,-78.37005241,-1.447785891
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,218,Ecuador,2011.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ECU,-78.37005241,-1.447785891
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,218,Ecuador,2012.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ECU,-78.37005241,-1.447785891
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,218,Ecuador,2013.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ECU,-78.37005241,-1.447785891
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,218,Ecuador,2014.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ECU,-78.37005241,-1.447785891
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,218,Ecuador,2015.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ECU,-78.37005241,-1.447785891
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,218,Ecuador,2016.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ECU,-78.37005241,-1.447785891
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,222,El Salvador,2010.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLV,-88.86862995,13.73603564
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,222,El Salvador,2011.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLV,-88.86862995,13.73603564
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,222,El Salvador,2012.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLV,-88.86862995,13.73603564
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,222,El Salvador,2013.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLV,-88.86862995,13.73603564
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,222,El Salvador,2014.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLV,-88.86862995,13.73603564
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,222,El Salvador,2015.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLV,-88.86862995,13.73603564
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,222,El Salvador,2016.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLV,-88.86862995,13.73603564
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,232,Eritrea,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ERI,38.11074289,16.12894644
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,232,Eritrea,2016.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ERI,38.11074289,16.12894644
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,748,Eswatini,2014.0,,67,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWZ,31.50149288,-26.56471011
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,748,Eswatini,2015.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWZ,31.50149288,-26.56471011
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,748,Eswatini,2016.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWZ,31.50149288,-26.56471011
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,231,Ethiopia,2011.0,,12,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ETH,39.63505296,8.631223181
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,231,Ethiopia,2012.0,,38,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ETH,39.63505296,8.631223181
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,231,Ethiopia,2013.0,,63,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ETH,39.63505296,8.631223181
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,231,Ethiopia,2014.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ETH,39.63505296,8.631223181
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,231,Ethiopia,2015.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ETH,39.63505296,8.631223181
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,231,Ethiopia,2016.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ETH,39.63505296,8.631223181
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2008.0,,12,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2009.0,,18,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2010.0,,37,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2011.0,,40,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2012.0,,43,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2013.0,,43,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2014.0,,45,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2015.0,,45,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,150,Europe,2016.0,,54,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,242,Fiji,2013.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FJI,177.9660884,-17.83301566
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,242,Fiji,2014.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FJI,177.9660884,-17.83301566
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,242,Fiji,2015.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FJI,177.9660884,-17.83301566
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,242,Fiji,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FJI,177.9660884,-17.83301566
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,246,Finland,2010.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FIN,23.308447,61.91586738
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,246,Finland,2011.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FIN,23.308447,61.91586738
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,246,Finland,2012.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FIN,23.308447,61.91586738
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,246,Finland,2013.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FIN,23.308447,61.91586738
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,246,Finland,2014.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FIN,23.308447,61.91586738
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,246,Finland,2015.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FIN,23.308447,61.91586738
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,246,Finland,2016.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FIN,23.308447,61.91586738
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,250,France,2010.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FRA,2.457288129,46.62660861
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,250,France,2011.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FRA,2.457288129,46.62660861
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,250,France,2012.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FRA,2.457288129,46.62660861
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,250,France,2013.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FRA,2.457288129,46.62660861
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,250,France,2014.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FRA,2.457288129,46.62660861
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,250,France,2015.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FRA,2.457288129,46.62660861
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,250,France,2016.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FRA,2.457288129,46.62660861
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,270,Gambia,2010.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GMB,-15.39944785,13.45295927
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,270,Gambia,2011.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GMB,-15.39944785,13.45295927
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,270,Gambia,2012.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GMB,-15.39944785,13.45295927
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,270,Gambia,2013.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GMB,-15.39944785,13.45295927
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,270,Gambia,2014.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GMB,-15.39944785,13.45295927
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,270,Gambia,2015.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GMB,-15.39944785,13.45295927
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,270,Gambia,2016.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GMB,-15.39944785,13.45295927
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,268,Georgia,2015.0,,16,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GEO,43.3713615,42.04813028
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,268,Georgia,2016.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GEO,43.3713615,42.04813028
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2008.0,,68,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2009.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2010.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2011.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2012.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2013.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2014.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2015.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,276,Germany,2016.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,DEU,10.3806066,51.08862743
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,288,Ghana,2012.0,,43,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GHA,-1.205623522,7.964825185
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,288,Ghana,2013.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GHA,-1.205623522,7.964825185
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,288,Ghana,2014.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GHA,-1.205623522,7.964825185
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,288,Ghana,2015.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GHA,-1.205623522,7.964825185
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,288,Ghana,2016.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GHA,-1.205623522,7.964825185
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,300,Greece,2012.0,,32,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GRC,22.58307827,39.47301873
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,300,Greece,2013.0,,32,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GRC,22.58307827,39.47301873
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,300,Greece,2014.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GRC,22.58307827,39.47301873
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,300,Greece,2015.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GRC,22.58307827,39.47301873
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,300,Greece,2016.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GRC,22.58307827,39.47301873
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,320,Guatemala,2013.0,,24,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GTM,-91.2312746,15.00273719
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,320,Guatemala,2014.0,,51,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GTM,-91.2312746,15.00273719
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,320,Guatemala,2015.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GTM,-91.2312746,15.00273719
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,320,Guatemala,2016.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GTM,-91.2312746,15.00273719
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,624,Guinea-Bissau,2015.0,,10,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GNB,-14.40182514,12.11760394
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,624,Guinea-Bissau,2016.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GNB,-14.40182514,12.11760394
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,328,Guyana,2011.0,,50,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GUY,-58.97322037,4.788012784
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,328,Guyana,2012.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GUY,-58.97322037,4.788012784
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,328,Guyana,2013.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GUY,-58.97322037,4.788012784
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,328,Guyana,2014.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GUY,-58.97322037,4.788012784
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,328,Guyana,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GUY,-58.97322037,4.788012784
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,328,Guyana,2016.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GUY,-58.97322037,4.788012784
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,340,Honduras,2011.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HND,-86.59974381,14.82243161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,340,Honduras,2012.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HND,-86.59974381,14.82243161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,340,Honduras,2013.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HND,-86.59974381,14.82243161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,340,Honduras,2014.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HND,-86.59974381,14.82243161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,340,Honduras,2015.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HND,-86.59974381,14.82243161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,340,Honduras,2016.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HND,-86.59974381,14.82243161
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,348,Hungary,2011.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HUN,19.41221519,47.1651448
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,348,Hungary,2012.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HUN,19.41221519,47.1651448
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,348,Hungary,2013.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HUN,19.41221519,47.1651448
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,348,Hungary,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HUN,19.41221519,47.1651448
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,348,Hungary,2015.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HUN,19.41221519,47.1651448
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,348,Hungary,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,HUN,19.41221519,47.1651448
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,352,Iceland,2012.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISL,-19.02116966,64.79134763
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,352,Iceland,2013.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISL,-19.02116966,64.79134763
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,352,Iceland,2014.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISL,-19.02116966,64.79134763
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,352,Iceland,2015.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISL,-19.02116966,64.79134763
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,352,Iceland,2016.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISL,-19.02116966,64.79134763
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,372,Ireland,2010.0,,43,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,IRL,-7.121425272,53.25274054
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,372,Ireland,2011.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,IRL,-7.121425272,53.25274054
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,372,Ireland,2012.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,IRL,-7.121425272,53.25274054
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,372,Ireland,2013.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,IRL,-7.121425272,53.25274054
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,372,Ireland,2014.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,IRL,-7.121425272,53.25274054
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,372,Ireland,2015.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,IRL,-7.121425272,53.25274054
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,372,Ireland,2016.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,IRL,-7.121425272,53.25274054
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,376,Israel,2011.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISR,34.62277992,31.06164552
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,376,Israel,2012.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISR,34.62277992,31.06164552
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,376,Israel,2013.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISR,34.62277992,31.06164552
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,376,Israel,2014.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISR,34.62277992,31.06164552
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,376,Israel,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISR,34.62277992,31.06164552
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,376,Israel,2016.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ISR,34.62277992,31.06164552
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2008.0,,60,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2009.0,,66,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2010.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2011.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2012.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2013.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2014.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2015.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,380,Italy,2016.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ITA,12.57022427,42.79917282
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,392,Japan,2015.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,JPN,139.2716103,36.6554539
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,392,Japan,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,JPN,139.2716103,36.6554539
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,398,Kazakhstan,2012.0,,37,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KAZ,66.65359159,48.01963494
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,398,Kazakhstan,2013.0,,52,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KAZ,66.65359159,48.01963494
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,398,Kazakhstan,2014.0,,58,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KAZ,66.65359159,48.01963494
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,398,Kazakhstan,2015.0,,74,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KAZ,66.65359159,48.01963494
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,398,Kazakhstan,2016.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KAZ,66.65359159,48.01963494
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,404,Kenya,2011.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KEN,37.86096816,0.534797278
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,404,Kenya,2012.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KEN,37.86096816,0.534797278
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,404,Kenya,2013.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KEN,37.86096816,0.534797278
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,404,Kenya,2014.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KEN,37.86096816,0.534797278
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,404,Kenya,2015.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KEN,37.86096816,0.534797278
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,404,Kenya,2016.0,,78,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KEN,37.86096816,0.534797278
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,296,Kiribati,2013.0,,40,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KIR,-157.5643005,1.768837732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,296,Kiribati,2014.0,,57,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KIR,-157.5643005,1.768837732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,296,Kiribati,2015.0,,74,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KIR,-157.5643005,1.768837732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,296,Kiribati,2016.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KIR,-157.5643005,1.768837732
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2008.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2009.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2010.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2011.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2013.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2014.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2015.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,414,Kuwait,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KWT,47.49305029,29.53949468
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2010.0,,2,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2011.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2012.0,,23,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2013.0,,31,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2014.0,,53,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2015.0,,60,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,432,Landlocked developing countries (LLDCs),2016.0,,70,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,418,Lao People's Democratic Republic,2014.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LAO,101.9901968,20.27482773
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,418,Lao People's Democratic Republic,2015.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LAO,101.9901968,20.27482773
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,418,Lao People's Democratic Republic,2016.0,,78,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LAO,101.9901968,20.27482773
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2008.0,,2.99945,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2009.0,,10.72789,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2010.0,,35.48784,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2011.0,,60.30619,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2012.0,,71.20318,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2013.0,,73.69062,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2014.0,,78.87612,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2015.0,,82.23396,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,419,Latin America and the Caribbean,2016.0,,80.90851,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,428,Latvia,2011.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LVA,26.42461876,56.64196636
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,428,Latvia,2012.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LVA,26.42461876,56.64196636
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,428,Latvia,2013.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LVA,26.42461876,56.64196636
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,428,Latvia,2014.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LVA,26.42461876,56.64196636
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,428,Latvia,2015.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LVA,26.42461876,56.64196636
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,428,Latvia,2016.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LVA,26.42461876,56.64196636
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2010.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2011.0,,7,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2012.0,,15,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2013.0,,30,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2014.0,,52,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2015.0,,63,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,199,Least Developed Countries (LDCs),2016.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,426,Lesotho,2015.0,,29,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LSO,28.25362195,-29.58041814
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,426,Lesotho,2016.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LSO,28.25362195,-29.58041814
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,430,Liberia,2014.0,,45,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LBR,-9.311879038,6.448381009
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,430,Liberia,2015.0,,56,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LBR,-9.311879038,6.448381009
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,430,Liberia,2016.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LBR,-9.311879038,6.448381009
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,434,Libya,2014.0,,39,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LBY,18.0295985,27.04042819
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,434,Libya,2015.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LBY,18.0295985,27.04042819
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,434,Libya,2016.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LBY,18.0295985,27.04042819
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,440,Lithuania,2016.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LTU,23.90517807,55.33680309
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2008.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2009.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2010.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2011.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2012.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2013.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,442,Luxembourg,2016.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,LUX,6.092656563,49.77679538
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,450,Madagascar,2013.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDG,46.6982339,-19.38514785
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,450,Madagascar,2014.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDG,46.6982339,-19.38514785
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,450,Madagascar,2015.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDG,46.6982339,-19.38514785
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,450,Madagascar,2016.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDG,46.6982339,-19.38514785
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,454,Malawi,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MWI,33.4884625,-13.40819859
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,454,Malawi,2013.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MWI,33.4884625,-13.40819859
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,454,Malawi,2014.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MWI,33.4884625,-13.40819859
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,454,Malawi,2015.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MWI,33.4884625,-13.40819859
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,454,Malawi,2016.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MWI,33.4884625,-13.40819859
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,466,Mali,2011.0,,56,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MLI,-3.522016039,17.35311254
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,466,Mali,2012.0,,68,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MLI,-3.522016039,17.35311254
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,466,Mali,2013.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MLI,-3.522016039,17.35311254
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,466,Mali,2014.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MLI,-3.522016039,17.35311254
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,466,Mali,2015.0,,53,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MLI,-3.522016039,17.35311254
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,466,Mali,2016.0,,70,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MLI,-3.522016039,17.35311254
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2009.0,,49,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2010.0,,24,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2011.0,,35,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2012.0,,46,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2013.0,,38,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2014.0,,29,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2015.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,584,Marshall Islands,2016.0,,51,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MHL,171.0839119,7.110213497
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,478,Mauritania,2013.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MRT,-10.33187259,20.26089546
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,478,Mauritania,2014.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MRT,-10.33187259,20.26089546
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,478,Mauritania,2015.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MRT,-10.33187259,20.26089546
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,478,Mauritania,2016.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MRT,-10.33187259,20.26089546
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,480,Mauritius,2016.0,,10,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MUS,57.568022,-20.28581998
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2012.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2013.0,,6,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2014.0,,7,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2015.0,,26,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,54,Melanesia,2016.0,,29,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2008.0,,14,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2009.0,,46,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2010.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2011.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2013.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2014.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,484,Mexico,2016.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MEX,-102.5148166,23.93378032
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2009.0,,9,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2010.0,,30,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2011.0,,30,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2012.0,,32,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2013.0,,49,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2014.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2015.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,57,Micronesia,2016.0,,68,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,583,Micronesia (Federated States of),2010.0,,70,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FSM,158.225216,6.880670092
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,583,Micronesia (Federated States of),2011.0,,63,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FSM,158.225216,6.880670092
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,583,Micronesia (Federated States of),2012.0,,60,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FSM,158.225216,6.880670092
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,583,Micronesia (Federated States of),2013.0,,61,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FSM,158.225216,6.880670092
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,583,Micronesia (Federated States of),2014.0,,64,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FSM,158.225216,6.880670092
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,583,Micronesia (Federated States of),2015.0,,67,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FSM,158.225216,6.880670092
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,583,Micronesia (Federated States of),2016.0,,63,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,FSM,158.225216,6.880670092
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2011.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2012.0,,20,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2013.0,,33,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2014.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2015.0,,63,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,17,Middle Africa,2016.0,,65,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,504,Morocco,2010.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MAR,-6.281942841,31.8440131
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,504,Morocco,2011.0,,23,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MAR,-6.281942841,31.8440131
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,504,Morocco,2012.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MAR,-6.281942841,31.8440131
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,504,Morocco,2013.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MAR,-6.281942841,31.8440131
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,504,Morocco,2014.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MAR,-6.281942841,31.8440131
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,504,Morocco,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MAR,-6.281942841,31.8440131
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,504,Morocco,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MAR,-6.281942841,31.8440131
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,508,Mozambique,2013.0,,45,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MOZ,38.18479941,-14.27963886
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,508,Mozambique,2014.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MOZ,38.18479941,-14.27963886
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,508,Mozambique,2015.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MOZ,38.18479941,-14.27963886
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,508,Mozambique,2016.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MOZ,38.18479941,-14.27963886
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,104,Myanmar,2016.0,,14,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MMR,96.51752295,21.19332882
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,516,Namibia,2015.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NAM,17.21907885,-22.13817068
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,516,Namibia,2016.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NAM,17.21907885,-22.13817068
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,524,Nepal,2015.0,,5,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NPL,83.94678863,28.25866332
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,524,Nepal,2016.0,,46,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NPL,83.94678863,28.25866332
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2009.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2010.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2011.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2012.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2013.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,528,Netherlands,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NLD,5.331480568,51.86728884
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2009.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2010.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2011.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2012.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2013.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,554,New Zealand,2016.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NZL,170.4755673,-43.98721568
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,558,Nicaragua,2011.0,,61,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIC,-85.03060315,12.84210839
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,558,Nicaragua,2012.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIC,-85.03060315,12.84210839
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,558,Nicaragua,2013.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIC,-85.03060315,12.84210839
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,558,Nicaragua,2014.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIC,-85.03060315,12.84210839
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,558,Nicaragua,2015.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIC,-85.03060315,12.84210839
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,558,Nicaragua,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIC,-85.03060315,12.84210839
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,562,Niger,2014.0,,13,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NER,9.400167877,17.42143036
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,562,Niger,2015.0,,49,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NER,9.400167877,17.42143036
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,562,Niger,2016.0,,64,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NER,9.400167877,17.42143036
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,566,Nigeria,2015.0,,13,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NGA,8.097363256,9.585789025
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,566,Nigeria,2016.0,,26,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NGA,8.097363256,9.585789025
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2009.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2010.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2011.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2013.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2014.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2015.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,570,Niue,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NIU,-169.8601693,-19.05000475
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2011.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2012.0,,9,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2013.0,,16,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2014.0,,33,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2015.0,,33,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,15,Northern Africa,2016.0,,44,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2008.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2009.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2010.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2011.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2012.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2013.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,746,Northern Africa (exc. Sudan),2016.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2008.0,,88.7891,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2009.0,,89.37687,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2010.0,,89.99677,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2011.0,,91.56223,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2012.0,,90.32885,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2013.0,,90.85021,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2014.0,,91.7608,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2015.0,,91.76517,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,21,Northern America,2016.0,,91.77348,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2008.0,,10,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2009.0,,18,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2010.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2011.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2012.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2013.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2014.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2015.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,154,Northern Europe,2016.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2008.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2009.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2010.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2011.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2012.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2013.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2014.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,578,Norway,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,NOR,11.47846389,61.34311134
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2008.0,,43,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2009.0,,53,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2010.0,,53,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2011.0,,54,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2012.0,,54,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2013.0,,56,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2014.0,,57,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2015.0,,65,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,9,Oceania,2016.0,,67,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2009.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2010.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2011.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2013.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2014.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2015.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,512,Oman,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,OMN,57.87743482,21.98805614
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,586,Pakistan,2013.0,,66,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAK,68.80479684,29.36491634
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,586,Pakistan,2014.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAK,68.80479684,29.36491634
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,586,Pakistan,2015.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAK,68.80479684,29.36491634
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,586,Pakistan,2016.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAK,68.80479684,29.36491634
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2008.0,,7,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2009.0,,18,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2010.0,,45,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2011.0,,61,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2012.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2013.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,585,Palau,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PLW,134.5733878,7.502307591
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,591,Panama,2010.0,,48,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAN,-81.26616623,8.450965746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,591,Panama,2011.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAN,-81.26616623,8.450965746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,591,Panama,2012.0,,62,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAN,-81.26616623,8.450965746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,591,Panama,2013.0,,68,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAN,-81.26616623,8.450965746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,591,Panama,2014.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAN,-81.26616623,8.450965746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,591,Panama,2015.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAN,-81.26616623,8.450965746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,591,Panama,2016.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PAN,-81.26616623,8.450965746
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,598,Papua New Guinea,2015.0,,20,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PNG,145.8587761,-6.756057077
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,598,Papua New Guinea,2016.0,,20,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PNG,145.8587761,-6.756057077
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,600,Paraguay,2012.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PRY,-60.54854225,-21.70216237
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,600,Paraguay,2013.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PRY,-60.54854225,-21.70216237
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,600,Paraguay,2014.0,,88,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PRY,-60.54854225,-21.70216237
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,600,Paraguay,2015.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PRY,-60.54854225,-21.70216237
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,600,Paraguay,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PRY,-60.54854225,-21.70216237
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2009.0,,9,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2010.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2011.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2012.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2013.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2014.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2015.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,604,Peru,2016.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PER,-71.82093277,-13.58939705
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,608,Philippines,2014.0,,35,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PHL,120.8601418,14.16591706
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,608,Philippines,2015.0,,17,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PHL,120.8601418,14.16591706
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,608,Philippines,2016.0,,36,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PHL,120.8601418,14.16591706
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2012.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2013.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2014.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2015.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,61,Polynesia,2016.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2009.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2010.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2011.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2012.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2013.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2014.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,634,Qatar,2016.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,QAT,51.19152467,25.28355379
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,410,Republic of Korea,2015.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KOR,127.8610254,36.45201023
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,410,Republic of Korea,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,KOR,127.8610254,36.45201023
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,498,Republic of Moldova,2013.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDA,28.4650624,47.20236795
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,498,Republic of Moldova,2014.0,,28,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDA,28.4650624,47.20236795
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,498,Republic of Moldova,2015.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDA,28.4650624,47.20236795
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,498,Republic of Moldova,2016.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,MDA,28.4650624,47.20236795
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,643,Russian Federation,2016.0,,35,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RUS,99.01404926,61.61899849
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,646,Rwanda,2010.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RWA,29.92310194,-1.999842114
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,646,Rwanda,2011.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RWA,29.92310194,-1.999842114
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,646,Rwanda,2012.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RWA,29.92310194,-1.999842114
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,646,Rwanda,2013.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RWA,29.92310194,-1.999842114
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,646,Rwanda,2014.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RWA,29.92310194,-1.999842114
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,646,Rwanda,2015.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RWA,29.92310194,-1.999842114
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,646,Rwanda,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,RWA,29.92310194,-1.999842114
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,674,San Marino,2016.0,,12,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SMR,12.46329038,43.93841766
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,678,Sao Tome and Principe,2013.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,STP,6.609772265,0.241554875
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,678,Sao Tome and Principe,2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,STP,6.609772265,0.241554875
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,678,Sao Tome and Principe,2015.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,STP,6.609772265,0.241554875
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,678,Sao Tome and Principe,2016.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,STP,6.609772265,0.241554875
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2009.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2010.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2011.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2012.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2013.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2014.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2015.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,682,Saudi Arabia,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SAU,44.54763347,24.12594211
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,686,Senegal,2014.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SEN,-14.46636926,14.35920905
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,686,Senegal,2015.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SEN,-14.46636926,14.35920905
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,686,Senegal,2016.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SEN,-14.46636926,14.35920905
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,694,Sierra Leone,2011.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLE,-11.78306584,8.568604164
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,694,Sierra Leone,2012.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLE,-11.78306584,8.568604164
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,694,Sierra Leone,2013.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLE,-11.78306584,8.568604164
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,694,Sierra Leone,2014.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLE,-11.78306584,8.568604164
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,694,Sierra Leone,2015.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLE,-11.78306584,8.568604164
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,694,Sierra Leone,2016.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLE,-11.78306584,8.568604164
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2009.0,,17,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2010.0,,22,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2011.0,,40,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2012.0,,52,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2013.0,,60,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2014.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2015.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,702,Singapore,2016.0,,78,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SGP,103.8107883,1.361009155
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2009.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2010.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2011.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2012.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2013.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2014.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2015.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,703,Slovakia,2016.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVK,19.48495604,48.70741446
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,705,Slovenia,2015.0,,49,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVN,14.82209486,46.11958061
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,705,Slovenia,2016.0,,50,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SVN,14.82209486,46.11958061
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2009.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2010.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2011.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2012.0,,5,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2013.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2014.0,,13,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2015.0,,17,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,722,Small island developing States (SIDS),2016.0,,23,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,90,Solomon Islands,2015.0,,42,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLB,160.1584117,-9.622391719
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,90,Solomon Islands,2016.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SLB,160.1584117,-9.622391719
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2009.0,,10,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2010.0,,58,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2011.0,,62,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2012.0,,70,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2013.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2014.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2015.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,710,South Africa,2016.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZAF,24.67184355,-29.99957544
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2009.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2010.0,,22,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2011.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2012.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2013.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2014.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2015.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,5,South America,2016.0,,83,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2012.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2013.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2014.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2015.0,,7,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,35,South-Eastern Asia,2016.0,,13,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2009.0,,8,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2010.0,,49,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2011.0,,52,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2012.0,,61,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2013.0,,61,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2014.0,,66,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2015.0,,76,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,18,Southern Africa,2016.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2010.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2011.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2012.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2013.0,,9,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2014.0,,11,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2015.0,,16,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,34,Southern Asia,2016.0,,21,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2008.0,,22,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2009.0,,24,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2010.0,,26,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2011.0,,30,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2012.0,,35,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2013.0,,37,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2014.0,,41,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2015.0,,43,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,39,Southern Europe,2016.0,,43,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,275,State of Palestine,2012.0,,25,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PSE,35.25694122,31.94347933
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,275,State of Palestine,2013.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PSE,35.25694122,31.94347933
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,275,State of Palestine,2014.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PSE,35.25694122,31.94347933
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,275,State of Palestine,2015.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PSE,35.25694122,31.94347933
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,275,State of Palestine,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,PSE,35.25694122,31.94347933
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2010.0,,3,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2011.0,,12,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2012.0,,22,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2013.0,,36,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2014.0,,51,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2015.0,,59,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,202,Sub-Saharan Africa,2016.0,,65,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2008.0,,70,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2009.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2010.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2011.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2012.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2013.0,,72,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2014.0,,74,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2015.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,738,Sub-Saharan Africa (inc. Sudan),2016.0,,74,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,729,Sudan,2013.0,,30,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,729,Sudan,2014.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,729,Sudan,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,729,Sudan,2016.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2008.0,,60,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2009.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2010.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2011.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2012.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2013.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2014.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2015.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,752,Sweden,2016.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,SWE,14.3775338,60.60103109
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2008.0,,13,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2009.0,,25,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2010.0,,37,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2011.0,,50,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2012.0,,62,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2013.0,,75,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2014.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2015.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,756,Switzerland,2016.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,CHE,8.223158,46.96617097
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,768,Togo,2014.0,,34,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TGO,0.97835765,8.532096072
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,768,Togo,2015.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TGO,0.97835765,8.532096072
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,768,Togo,2016.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TGO,0.97835765,8.532096072
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,780,Trinidad and Tobago,2012.0,,39,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TTO,-61.29389504,10.41877263
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,780,Trinidad and Tobago,2013.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TTO,-61.29389504,10.41877263
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,780,Trinidad and Tobago,2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TTO,-61.29389504,10.41877263
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,780,Trinidad and Tobago,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TTO,-61.29389504,10.41877263
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,780,Trinidad and Tobago,2016.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TTO,-61.29389504,10.41877263
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2009.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2010.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2011.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2012.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2013.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2014.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2015.0,,97,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,792,Turkey,2016.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TUR,35.42890329,38.9899684
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,800,Uganda,2014.0,,50,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,UGA,32.39100438,1.279557331
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,800,Uganda,2015.0,,66,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,UGA,32.39100438,1.279557331
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,800,Uganda,2016.0,,78,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,UGA,32.39100438,1.279557331
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,784,United Arab Emirates,2010.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARE,53.98279159,23.43322219
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,784,United Arab Emirates,2011.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARE,53.98279159,23.43322219
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,784,United Arab Emirates,2012.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARE,53.98279159,23.43322219
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,784,United Arab Emirates,2013.0,,98,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARE,53.98279159,23.43322219
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,784,United Arab Emirates,2014.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARE,53.98279159,23.43322219
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,784,United Arab Emirates,2015.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARE,53.98279159,23.43322219
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,784,United Arab Emirates,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ARE,53.98279159,23.43322219
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,826,United Kingdom of Great Britain and Northern Ireland,2010.0,,89,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GBR,-2.23830539,53.27691757
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,826,United Kingdom of Great Britain and Northern Ireland,2011.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GBR,-2.23830539,53.27691757
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,826,United Kingdom of Great Britain and Northern Ireland,2012.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GBR,-2.23830539,53.27691757
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,826,United Kingdom of Great Britain and Northern Ireland,2013.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GBR,-2.23830539,53.27691757
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,826,United Kingdom of Great Britain and Northern Ireland,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GBR,-2.23830539,53.27691757
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,826,United Kingdom of Great Britain and Northern Ireland,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GBR,-2.23830539,53.27691757
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,826,United Kingdom of Great Britain and Northern Ireland,2016.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,GBR,-2.23830539,53.27691757
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,834,United Republic of Tanzania,2013.0,,80,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TZA,34.80521182,-6.265332606
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,834,United Republic of Tanzania,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TZA,34.80521182,-6.265332606
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,834,United Republic of Tanzania,2015.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TZA,34.80521182,-6.265332606
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,834,United Republic of Tanzania,2016.0,,96,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,TZA,34.80521182,-6.265332606
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2008.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2009.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2010.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2011.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2012.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2013.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2014.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2015.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,840,United States of America,2016.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,USA,-99.13830311,39.5277871
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,858,Uruguay,2010.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,URY,-56.01387025,-32.8002838
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,858,Uruguay,2011.0,,92,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,URY,-56.01387025,-32.8002838
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,858,Uruguay,2012.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,URY,-56.01387025,-32.8002838
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,858,Uruguay,2013.0,,93,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,URY,-56.01387025,-32.8002838
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,858,Uruguay,2014.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,URY,-56.01387025,-32.8002838
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,858,Uruguay,2015.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,URY,-56.01387025,-32.8002838
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,858,Uruguay,2016.0,,94,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,URY,-56.01387025,-32.8002838
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,860,Uzbekistan,2016.0,,99,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,UZB,63.11944558,41.77560518
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,862,Venezuela (Bolivarian Republic of),2015.0,,24,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,VEN,-66.15642084,7.121324748
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,862,Venezuela (Bolivarian Republic of),2016.0,,7,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,VEN,-66.15642084,7.121324748
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2008.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2009.0,,0,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2010.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2011.0,,6,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2012.0,,11,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2013.0,,14,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2014.0,,26,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2015.0,,39,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,11,Western Africa,2016.0,,50,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2008.0,,1,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2009.0,,38,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2010.0,,38,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2011.0,,48,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2012.0,,52,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2013.0,,55,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2014.0,,57,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2015.0,,58,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,145,Western Asia,2016.0,,59,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2008.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2009.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2010.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2011.0,,86,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2012.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2013.0,,82,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2014.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2015.0,,79,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,485,"Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2016.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2008.0,,25,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2009.0,,40,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2010.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2011.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2012.0,,84,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2013.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2014.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2015.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,155,Western Europe,2016.0,,85,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2008.0,,4,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2009.0,,7,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2010.0,,11,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2011.0,,15,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2012.0,,19,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2013.0,,26,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2014.0,,32,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2015.0,,37,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,1,World,2016.0,,42,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,,,
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,887,Yemen,2011.0,,41,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,YEM,45.22389143,15.22242099
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,887,Yemen,2012.0,,67,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,YEM,45.22389143,15.22242099
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,887,Yemen,2013.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,YEM,45.22389143,15.22242099
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,887,Yemen,2014.0,,73,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,YEM,45.22389143,15.22242099
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,887,Yemen,2015.0,,69,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,YEM,45.22389143,15.22242099
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,887,Yemen,2016.0,,71,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,YEM,45.22389143,15.22242099
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,894,Zambia,2014.0,,77,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZMB,27.850329,-14.59701056
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,894,Zambia,2015.0,,81,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZMB,27.850329,-14.59701056
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,894,Zambia,2016.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZMB,27.850329,-14.59701056
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,716,Zimbabwe,2012.0,,21,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZWE,29.86909584,-19.00075492
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,716,Zimbabwe,2013.0,,95,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZWE,29.86909584,-19.00075492
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,716,Zimbabwe,2014.0,,91,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZWE,29.86909584,-19.00075492
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,716,Zimbabwe,2015.0,,87,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZWE,29.86909584,-19.00075492
3,Ensure healthy lives and promote well-being for all at all ages,3.b,"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all",3.b.1,Proportion of the target population covered by all vaccines included in their national programme,2,SH_ACS_PCV3,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%),2019.Q1.G.01,G,Global,E,Estimated data,PERCENT,Percentage,716,Zimbabwe,2016.0,,90,Float,"WHO/UNICEF coverage estimates 2016 revision, July 2017",,ZWE,29.86909584,-19.00075492
